close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

0.8449 +0.1760 (+26.31%)
Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
After-Hours Market Movers: Gainers and Decliners From Today's U.S. Session ↗
Via Chartmill
Top Gainers and Losers: Nov. 5 Low-Priced Market Movers ↗
Via Chartmill
Today's US Session: Top Stock Gainers and Losers ↗
Via Chartmill
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $21 Million Public Offering to Support Buntanetap Clinical Development
Via Investor Brand Network
Notable Gap Movers on Nov. 5, 2026: AEHL and ZNB Gap Higher; VCYT and MNTN Gap Lower ↗
Via Chartmill
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Proposed Public Offering to Support Buntanetap Clinical Development
Via Investor Brand Network
Premarket Movers: Gainers and Decliners on Nov. 5, 2026 ↗
Via Chartmill
News headline image
Annovis Announces Pricing of $21.0 Million Public Offering
From Annovis Bio Inc.
Via GlobeNewswire
After-Hours Market Movers: Nov. 4, 2026 Gainers and Losers ↗
Via Chartmill
News headline image
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
From Annovis Bio Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Two November Biotechnology Industry Conferences
Via Investor Brand Network
News headline image
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates 
From Annovis Bio Inc.
Via GlobeNewswire
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present Buntanetap Research and Phase 3 Trial Updates at Alzheimer Conference
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Annovis to Attend the CTAD 2026 with Three Presentations
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Collaborates With Weave Bio to Support Buntanetap NDA Preparation
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA ↗
Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug... 
Via MarketBeat
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Host Corporate Update Webinar on Clinical Programs and Milestones
Via Investor Brand Network
News headline image
Annovis to Host Corporate Update Webinar on September 2, 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Promotes Cheng Fang to Chief Scientific Officer
Via Investor Brand Network
News headline image
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
From Annovis Bio Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Regains NYSE Listing Compliance
Via Investor Brand Network
News headline image
Annovis Bio Regains NYSE Listing Compliance
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $15 Million Public Offering of Common Stock and Warrants
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Proposed Public Offering of Common Stock and Warrants
Via Investor Brand Network
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.